PMID- 32164911
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20201105
IS  - 2211-0356 (Electronic)
IS  - 2211-0348 (Linking)
VI  - 38
DP  - 2020 Feb
TI  - Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment 
      and initial characterization of a patient registry.
PG  - 101448
LID - S2211-0348(19)30436-5 [pii]
LID - 10.1016/j.msard.2019.101448 [doi]
AB  - OBJECTIVE: To describe the clinical and radiological characteristics of 
      neuromyelitis optica spectrum disorders (NMOSD) patients from the Arabian Gulf 
      relative to anti-aquaporin 4 antibody serostatus. METHODS: Retrospective 
      multicentre study of hospital records of patients diagnosed with NMOSD based on 
      2015 International Panel on NMOSD Diagnosis (IPND) consensus criteria. RESULTS: 
      One hundred forty four patients were evaluated, 64.3% were anti-AQP4 antibody 
      positive. Mean age at onset and disease duration were 31+/-12 and 7 +/- 6 years 
      respectively. Patients were predominantly female (4.7:1). Overall; relapsing 
      course (80%) was more common than monophasic (20%). Optic neuritis was the most 
      frequent presentation (48.6%), regardless of serostatus. The proportion of 
      patients (54.3%) with visual acuity of </= 0.1 was higher in the seropositive group 
      (p = 0.018). Primary presenting symptoms of transverse myelitis (TM) were 
      observed in 29% of patients, and were the most significant correlate of 
      hospitalization (p<0.001). Relative to anti-APQ4 serostatus, there were no 
      significant differences in terms of age of onset, course, relapse rates or 
      efficacy outcomes except for oligoclonal bands (OCB), which were more often 
      present in seronegative patients (40% vs.22.5%; p = 0.054). Irrespective of 
      serostatus, several disease modifying therapies were instituted including 
      steroids or immunosuppressives, mostly, rituximab and azathioprine in the cohort 
      irrespective of serostatus. The use of rituximab resulted in reduction in disease 
      activity. CONCLUSION: This is the first descriptive NMOSD cohort in the Arabian 
      Gulf region. Seropositive patients were more prevalent with female predominance. 
      Relapsing course was more common than monophasic. However, anti-AQP4 serostatus 
      did not impact disease duration, relapse rate or therapeutic effectiveness. These 
      findings offer new insights into natural history of NMOSD in patients of the 
      Arabian Gulf and allow comparison with patient populations in different World 
      regions.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Shosha, Eslam
AU  - Shosha E
AD  - Departments of Neurology, Prince Sultan Military Medical City, Riyadh, Saudi 
      Arabia; Department of Clinical Neurological Sciences, University of Western 
      Ontario, London, Ontario, Canada. Electronic address: dr.eslamshosha@hotmail.com.
FAU - Al Asmi, Abdulla
AU  - Al Asmi A
AD  - Neurology Unit, Department of Medicine, Sultan Qaboos University and Hospital, 
      Oman.
FAU - Nasim, Eman
AU  - Nasim E
AD  - Departments of Neurology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
FAU - Inshasi, Jihad
AU  - Inshasi J
AD  - Neurology Department, Rashid Hospital and Dubai Medical College, Dubai, UAE.
FAU - Abdulla, Fatima
AU  - Abdulla F
AD  - Neuroscience Department, Salmaniya Medical Complex, Manama, Bahrain.
FAU - Al Malik, Yaser
AU  - Al Malik Y
AD  - Neurology Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King 
      Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
FAU - Althobaiti, Ahmed
AU  - Althobaiti A
AD  - Department of Neurology, King Saud Medical City, Riyadh, Saudi Arabia.
FAU - Alzawahmah, Mohamed
AU  - Alzawahmah M
AD  - Departments of Neurology, Prince Sultan Military Medical City, Riyadh, Saudi 
      Arabia.
FAU - Alnajashi, Hind A
AU  - Alnajashi HA
AD  - Neurology Division, Internal Medicine Department, King Abdulaziz University, 
      Jeddah, Saudi Arabia; Neuroscience Department, International Medical Center, 
      Jeddah, Saudi Arabia.
FAU - Binfalah, Mohamed
AU  - Binfalah M
AD  - Department of Neurology, King Abdulla Medical City, Bahrain.
FAU - AlHarbi, Awad
AU  - AlHarbi A
AD  - Neurology Division, Internal Medicine Department, Prince Mohammed Bin Abdulaziz 
      Hospital, Riyadh, Saudi Arabia.
FAU - Thubaiti, Ibtisam A
AU  - Thubaiti IA
AD  - Neurology Department, King Fahad Military Medical Complex, Dhahran, Saudi Arabia.
FAU - Ahmed, Samar F
AU  - Ahmed SF
AD  - Department of Neurology, Ibn Sina Hospital, Kuwait; Faculty of Medicine, Minia 
      University, Egypt.
FAU - Al-Hashel, Jasem
AU  - Al-Hashel J
AD  - Department of Neurology, Ibn Sina Hospital, Kuwait.
FAU - Elyas, Mortada
AU  - Elyas M
AD  - Neurology Unit, Department of Medicine, Sultan Qaboos University and Hospital, 
      Oman.
FAU - Nandhagopal, Ramachandiran
AU  - Nandhagopal R
AD  - Neurology Unit, Department of Medicine, Sultan Qaboos University and Hospital, 
      Oman.
FAU - Gujjar, Arunodaya
AU  - Gujjar A
AD  - Neurology Unit, Department of Medicine, Sultan Qaboos University and Hospital, 
      Oman.
FAU - Harbi, Talal Al
AU  - Harbi TA
AD  - Departments of Neurology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
FAU - Towaijri, Ghadah Al
AU  - Towaijri GA
AD  - Neurology Department, King Fahad Medical City, Riyadh, Saudi Arabia.
FAU - Alsharooqi, Isa A
AU  - Alsharooqi IA
AD  - Neuroscience Department, Salmaniya Medical Complex, Manama, Bahrain.
FAU - AlMaawi, Ahmed
AU  - AlMaawi A
AD  - Neuroscience Department, Salmaniya Medical Complex, Manama, Bahrain.
FAU - Al Khathaami, Ali M
AU  - Al Khathaami AM
AD  - Neurology Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King 
      Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
FAU - Alotaibi, Naser
AU  - Alotaibi N
AD  - Neurology Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King 
      Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
FAU - Nahrir, Shahpar
AU  - Nahrir S
AD  - Department of Neurology, King Saud Medical City, Riyadh, Saudi Arabia.
FAU - Al Rasheed, Abdulrahman A
AU  - Al Rasheed AA
AD  - Departments of Neurology, Prince Sultan Military Medical City, Riyadh, Saudi 
      Arabia.
FAU - Al Qahtani, Mohammed
AU  - Al Qahtani M
AD  - Neurology Department, King Fahad Military Medical Complex, Dhahran, Saudi Arabia.
FAU - Alawi, Sadaga
AU  - Alawi S
AD  - Departments of Neurology, Prince Sultan Military Medical City, Riyadh, Saudi 
      Arabia.
FAU - Hundallah, Khalid
AU  - Hundallah K
AD  - Departments of Neurology, Prince Sultan Military Medical City, Riyadh, Saudi 
      Arabia.
FAU - Jumah, Mohammed
AU  - Jumah M
AD  - Neurology Department, King Fahad Medical City, Riyadh, Saudi Arabia.
FAU - Alroughani, Raed
AU  - Alroughani R
AD  - Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait.
CN  - with the Guthy-Jackson Charitable Foundation International Clinical Consortium
LA  - eng
PT  - Journal Article
DEP - 20191019
PL  - Netherlands
TA  - Mult Scler Relat Disord
JT  - Multiple sclerosis and related disorders
JID - 101580247
RN  - 0 (Immunoglobulin G)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myelin-Oligodendrocyte Glycoprotein/*drug effects/immunology
MH  - Neoplasm Recurrence, Local/*drug therapy
MH  - Neuromyelitis Optica/*drug therapy
MH  - Optic Neuritis/drug therapy
MH  - Registries
MH  - Visual Acuity/drug effects
OTO - NOTNLM
OT  - Arabian Gulf
OT  - Clinical phenotypes
OT  - NMOSD
COIS- Declaration of Competing Interest EN, AT, AK, MF, SN, MZ, SF, AA.A, JA, MJ. TA, 
      AA, ME, RN, AG, IA, AM, NO, MQ, SA, KH has nothing to disclose E.Shosha has 
      received honoraria for scientific lectures from Biologix, Merck, Hikma, travel 
      payment from, Biologix, Sanofi, Merck, and Roche and served on the scientific 
      advisory board for Biologix, Merck, and Sanofi. A. Al Asmi received honoraria for 
      serving in scientific advisory board from Novartis, Merck, and Roche and travel 
      payment from, Biologix, Bayer, Sanofi, Merck, Novartis, and Roche. J. Inshasi 
      received honoraria for serving in scientific advisory board meetings from Biogen, 
      Novartis, Merck, Sanofi and Roche Y. Al Malik received Compensation for advisory 
      board participation and conference travel (Genzyme, Merck, and Roche). H. 
      Alnajashi received honoraria as a speaker from Biogen, Novartis, and Roche. G. 
      Altowaijri received honoraria for speaking for Novartis and advisory board for 
      genzyme. F. Abdulla served in advisory board for Roche and Novartis Ibtisam 
      A.Thubaiti worked on scientific advisory board for Merck-Serono and eceived 
      speaker's honoraria from Novartis and Merck-Serono. R. Alroughani received 
      honoraria as a speaker and for serving in scientific advisory board from Biogen, 
      Bayer, Novartis, Merck, Sanofi and Roche.
EDAT- 2020/03/14 06:00
MHDA- 2020/11/06 06:00
CRDT- 2020/03/14 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2019/10/01 00:00 [revised]
PHST- 2019/10/13 00:00 [accepted]
PHST- 2020/03/14 06:00 [entrez]
PHST- 2020/03/14 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
AID - S2211-0348(19)30436-5 [pii]
AID - 10.1016/j.msard.2019.101448 [doi]
PST - ppublish
SO  - Mult Scler Relat Disord. 2020 Feb;38:101448. doi: 10.1016/j.msard.2019.101448. 
      Epub 2019 Oct 19.